This is an old revision of this page, as edited by BigDwiki(talk | contribs) at 23:21, 29 October 2019(Minor Clean Up and Fixes, added Empty section (1) tag). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 23:21, 29 October 2019 by BigDwiki(talk | contribs)(Minor Clean Up and Fixes, added Empty section (1) tag)
Anoctamin 5 (ANO5) is a protein that in humans is encoded by the ANO5 gene.
Function
The ANO5 gene provides instructions for making a protein called anoctamin-5. While the specific function of this protein is not well understood, it belongs to a family of proteins, called anoctamins, that act as chloride channels. Chloride channels, which transport negatively charged chlorine atoms (chloride ions) in and out of cells, play a key role in a cell's ability to generate and transmit electrical signals. Most anoctamin proteins function as chloride channels that are turned on (activated) in the presence of positively charged calcium atoms (calcium ions); these channels are known as calcium-activated chloride channels. The mechanism for this calcium activation is unclear. Anoctamin proteins are also involved in maintaining the membrane that surrounds cells and repairing the membrane if damaged.[5]
The anoctamin-5 protein is most abundant in muscles used for movement (skeletal muscles). For the body to move normally, skeletal muscles must tense (contract) and relax in a coordinated way. The regulation of chloride flow within muscle cells plays a role in controlling muscle contraction and relaxation.[5]
The anoctamin-5 protein is also found in other cells including heart (cardiac) muscle cells and bone cells. The anoctamin-5 protein may be important for the development of muscle and bone before birth.[5]
Diseases associated with ANO5 mutations
Limb Girdle Muscular Dystrophy 2L (LGMD2L) and Miyoshi Distal Myopathy 3 (MMD3)
These forms of muscular dystrophy are inherited in an autosomal recessive pattern, meaning that to be affected a person must have mutations on both copies of the gene, and males and females are equally likely to be affected.
Clinically, LGMD2L and MMD3 were considered different diseases before ANO5 was identified as the responsible gene; LGMD was used to describe initial weakness in proximal muscles (near the center of the body) while MMD to describe initial weakness in distal muscles.
Typical Symptoms
This section is empty. You can help by adding to it. (October 2019)
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ abcd"ANO5 gene". Genetics Home Reference. US National Library of Medicine. Retrieved 24 July 2018. This article incorporates text from this source, which is in the public domain.
Further reading
Penttilä S, Palmio J, Udd B (November 2012). "ANO5-Related Muscle Diseases". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A, Penttilä S, Palmio J, Udd B (eds.). SourceGeneReviews [Internet]. Seattle (WA): University of Washington, Seattle. PMID23193613.